Preventing Thrombosis to Improve Outcomes in Heart Failure Patients

Area of Science:

• Cardiology
• Thrombosis Research
• Pharmacology

Background:

• Heart failure (HF) significantly elevates thrombotic event risk, particularly when comorbid with atrial fibrillation (AF).
• Coronary artery disease (CAD) in HF patients increases susceptibility to coronary thrombosis, leading to myocardial infarction and sudden cardiac death.
• Understanding these intertwined risks is crucial for effective patient management.

Purpose of the Study:

• To review the prothrombotic factors associated with heart failure.
• To provide an overview of current antithrombotic management strategies for HF patients.
• To differentiate therapeutic approaches based on the presence or absence of AF and CAD.

Main Methods:

• Literature review of studies on thrombosis in heart failure.
• Analysis of guidelines and clinical trial data on antithrombotic therapies.
• Synthesis of information on oral anticoagulants and antiplatelet agents in HF management.

Main Results:

• Oral anticoagulation is vital for HF patients with AF, with non-vitamin K antagonists as a preferred alternative to warfarin.
• Aspirin monotherapy is insufficient for stroke prevention in HF patients with AF.
• Routine oral anticoagulation is not recommended for HF without AF; antiplatelet therapy is indicated for those with concurrent CAD.

Conclusions:

• Antithrombotic management in HF requires careful consideration of individual patient factors, including AF and CAD.
• Non-vitamin K antagonists offer a safe and effective anticoagulation option for HF patients with AF.
• Tailored antiplatelet and anticoagulant strategies are essential for optimizing outcomes and reducing thrombotic risk in heart failure.